Факторы риска реактивации цитомегаловирусной инфекции у детей и подростков после различных видов аллогенной трансплантации гемопоэтических стволовых клеток

Risk factors of CMV replication in early period after allo-HSCT (D0‑D100) were – myeloablative conditioning – HR 3.74 (1.67–8.37), р = 0.001; unrelated donor – HR 2.18 (0.86–5.26), р = 0.10; HLA-matched donor – HR 0.24 (0.05–1.06), р = 0,06. In late posttransplant period (from D+100) significant risk factors of CMV-reactivation were (according to multivariate analysis) myeloablative conditioning – HR 13.17 (3.00–57.86), р = 0.001; combination of pretransplant remission of leukemia and using cyclosporine and methotrexate – HR 0.13 (0.03–0.50), р = 0.003; combination of aGVHD and CMV reactivation in early posttransplant period – HR 2.71 (0.86–8.50), р = 0.088; using of bone marrow – HR 0.37 (0.12–1.19), р = 0.095. We revealed the significant association of aGVHD and CMV-reactivation –OR 2.91 (1.07–7.92), р=0.006, and increased rate of cGVHD in patients with CMV replication at third month after allo-HSCT OR – 2.29 (1.03–5.08), р = 0.066. We revealed a tend to decreasing relapse risk in patients who had CMV-replication – HR 0.07 (0.004–1.17), р = 0.06. Cumulative incidence of CMV-disease was 28 %. CMV-disease was lethal in 44 % patients.

[1]  А. А. Бологов,et al.  Трансплантация гемопоэтических стволовых клеток у пациентов с синдромом Гурлер – эффективность миелоаблативного кондиционирования , 2015 .

[2]  E. V. Semenova,et al.  Бактериальные инфекции у пациентов детского и подросткового возраста после трансплантации аллогенных гемопоэтических стволовых клеток: этиология, структура, факторы риска , 2014 .

[3]  Xu Shi-xia,et al.  Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta‐analysis , 2011, Clinical transplantation.

[4]  Наталья Евгеньевна Иванова,et al.  Нетравматические внутричерепные кровоизлияния в Ханты-Мансийском автономном округе: заболеваемость, смертность, Структура, факторы риска , 2011 .

[5]  Е. В. Морозова,et al.  Острый миелобластный лейкоз и миелодиспластический синдром: применение азацитидина с профилактической и превентивной целью после аллогенной трансплантации гемопоэтических стволовых клеток , 2011 .

[6]  A. Gratwohl,et al.  Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  I. Kerridge,et al.  Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants , 2010, Bone Marrow Transplantation.

[8]  R. Martino,et al.  Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience , 2010, Bone Marrow Transplantation.

[9]  M. Maris,et al.  Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  G. Cook,et al.  Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.

[11]  E. Claas,et al.  Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning , 2007, Bone Marrow Transplantation.

[12]  S. Riddell,et al.  Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. , 2006, Haematologica.

[13]  P. Ljungman,et al.  Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. , 2006, Haematologica.

[14]  J. Schold,et al.  Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  M. Ortín,et al.  Cytomegalovirus Reactivation in Pediatric Hemopoietic Progenitors Transplant: A Retrospective Study on the Risk Factors and the Efficacy of Treatment , 2005, Journal of pediatric hematology/oncology.

[16]  D. Olive,et al.  Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen , 2004, Bone Marrow Transplantation.

[17]  M. N. Kim,et al.  The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell Transplantation Compared with Conventional Bone Marrow Transplantation , 2004, Journal of Korean medical science.

[18]  P. Ljungman,et al.  Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus , 2004, Transplantation.

[19]  W. Siegert,et al.  Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia , 2003, Bone Marrow Transplantation.

[20]  M. Haun,et al.  Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation , 2003, Annals of Hematology.

[21]  J. Garcia-conde,et al.  Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. , 2002, Blood.

[22]  A. Ganser,et al.  Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[23]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[24]  K. Fish,et al.  Reactivation of Latent Human Cytomegalovirus in CD14+ Monocytes Is Differentiation Dependent , 2001, Journal of Virology.

[25]  A. Nagler,et al.  Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen , 2001, Bone Marrow Transplantation.

[26]  H. Einsele,et al.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection , 2000, Bone Marrow Transplantation.

[27]  H. Prentice,et al.  Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. , 1998, Journal of immunology.

[28]  K. Fish,et al.  Reactivation of Latent Human Cytomegalovirus by Allogeneic Stimulation of Blood Cells from Healthy Donors , 1997, Cell.

[29]  J. Maciejewski,et al.  Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. , 1997, Blood.

[30]  G. Gahrton,et al.  VARIABLES PREDICTING BACTERIAL AND FUNGAL INFECTIONS AFTER ALLOGENEIC MARROW ENGRAFTMENT , 1987, Transplantation.